MGTA-117 Antibody

MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2) . MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy[1][2][3].

Product Specifications

UNSPSC

12352203

Target

ADC Antibody

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[MGTA-117Antibody]

References & Citations

[1]Artz A S, et al. TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB) [J]. 2022. |[2]Lanieri L, et al. A single dose of a novel anti-human CD117-amanitin antibody drug conjugate (ADC) engineered for a short half-life provides dual conditioning and anti-leukemic activity and extends survival compared to standard of care in multiple preclinical models of acute myeloid leukemia (AML) [J]. Blood, 2020, 136: 47-48. |[3]Kitawi R, et al. Advances in HIV Gene Therapy. Int J Mol Sci. 2024 Feb 28; 25 (5) :2771.